FY2025 EPS Estimates for Hologic Boosted by Leerink Partnrs

Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at Leerink Partnrs raised their FY2025 EPS estimates for shares of Hologic in a note issued to investors on Wednesday, December 11th. Leerink Partnrs analyst P. Souda now expects that the medical equipment provider will post earnings of $4.31 per share for the year, up from their previous estimate of $4.27. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Leerink Partnrs also issued estimates for Hologic’s Q4 2025 earnings at $1.14 EPS, Q1 2026 earnings at $1.12 EPS, Q2 2026 earnings at $1.16 EPS, Q3 2026 earnings at $1.20 EPS, Q4 2026 earnings at $1.21 EPS and FY2026 earnings at $4.69 EPS.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the previous year, the firm posted $0.89 earnings per share. The firm’s quarterly revenue was up 4.5% on a year-over-year basis.

A number of other analysts have also issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Tuesday, December 10th. Raymond James lifted their price target on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Leerink Partners decreased their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Royal Bank of Canada raised their target price on Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Finally, BNP Paribas upgraded Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Six analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $89.50.

Hologic Stock Performance

Hologic stock opened at $73.65 on Monday. The firm has a market capitalization of $16.71 billion, a PE ratio of 22.12, a price-to-earnings-growth ratio of 2.38 and a beta of 0.96. Hologic has a one year low of $70.24 and a one year high of $84.67. The stock’s 50 day moving average price is $79.32 and its 200 day moving average price is $78.64. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.75% of the company’s stock.

Institutional Investors Weigh In On Hologic

Several institutional investors and hedge funds have recently bought and sold shares of HOLX. State Street Corp grew its holdings in shares of Hologic by 0.8% during the third quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock valued at $847,944,000 after purchasing an additional 81,057 shares during the last quarter. FMR LLC boosted its position in Hologic by 64.0% during the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the period. The Manufacturers Life Insurance Company grew its stake in Hologic by 0.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock worth $208,051,000 after buying an additional 18,774 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Hologic by 8.6% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock worth $200,952,000 after buying an additional 195,285 shares during the period. Finally, Black Creek Investment Management Inc. lifted its stake in Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock valued at $173,669,000 after buying an additional 885,524 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.